3-Chloropropyltrimethylammonium-Kation | 95467-54-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Chloropropyltrimethylammonium-Kation
• 英文别名: γ-Chlorpropyl-trimethylammonium；<γ-Chlorpropyl-trimethylammonium>⁺；trimethyl-(3-chloro-propyl)-ammonium；Trimethyl-(3-chlor-propyl)-ammonium；Trimethyl-(γ-chlor-propyl)-ammonium；3-Chloropropyl(trimethyl)azanium
• CAS: 95467-54-2
• 化学式: C₆H₁₅ClN
• 分子量: 136.645
• InChiKey: QTWPCBRXUJSXRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-Chloropropyltrimethylammonium-Kation 在 sodium ethanolate 作用下， 生成 烯丙基三甲基氯化铵
  参考文献：
  名称：

  Rothstein, Journal of the Chemical Society, 1940, p. 1563

  摘要：

  DOI：

文献信息

• [EN] 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE ET COMPOSÉS CORRESPONDANTS UTILISÉS EN TANQUE QUE AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) UTILISÉS POUR LE TRAITEMENT DE, P.EX., DE L'ANGIOGENÈSE IMPLIQUÉE OU DE TROUBLES INFLAMMATOIRES
  申请人：IKENA ONCOLOGY INC

  公开号：WO2021127302A1

  公开（公告）日：2021-06-24

  2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

  2-(1H-吲哚-3-甲酰基)-噻唑-4-羧酰胺衍生物及相应的咪唑、噁唑和噻吩衍生物以及相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。本说明书揭示了示例化合物的合成和表征以及其药理数据（例如第27至32页和59至219页；示例1至8；化合物1-1至1-97；表1-a、2和3）。
• 3-Aminoindazole derivatives and process for preparation thereof
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0049779A1

  公开（公告）日：1982-04-21

  A compound of the formula (I): wherein W, is a hydrogen atom or a group wherein Y is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R, and R2 each independently is a hydrogen atom or a C1-6 alkyl group and R,, R2 and the adjacent nitrogen atom may form a C4-6 heterocyclic ring or a C4-6 heterocyclic ring containing an additional nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; W2 is a hydrogen atom or a group wherein Z is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R3 and R4 each independently is a hydrogen atom or a C1-6 alkyl group and R3, R4 and the adjacent nitrogen atom may form a C4-6 hetercyclic ring or a C4-6 heterocyclic ring containing an additional nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; when W, is a hydrogen atom, W2 is the group; and when W2 is a hydrogen atom, W, is the group; and the pharmaceutically acceptable acid addition salt thereof.

  式 (I) 的化合物： 其中 W，是氢原子或 其中 Y 是 C1-6 亚烷基或具有 C1-6 烷基取代基的 C1-6 亚烷基；R 和 R2 各自独立地是氢原子或 C1-6 烷基，且 R、R2 和相邻的氮原子可形成 C4-6 杂环或含有额外氮原子的 C4-6 杂环，且 C4-6 杂环可具有至少一个 C1-6 烷基、羟基或卤素原子； W2 是氢原子或 其中 Z 为 C1-6 亚烷基或具有 C1-6 烷基取代基的 C1-6 亚烷基；以及 R3 和 R4 各自独立地为氢原子或 C1-6 烷基，且 R3、R4 和相邻氮原子可形成 C4-6 杂环或含有额外氮原子的 C4-6 杂环，且 C4-6 杂环可具有至少一个 C1-6 烷基、羟基或卤素原子； 当 W 是氢原子时，W2 是 基团；以及 当 W2 是氢原子时，W, 是基团；及 基团；及其药学上可接受的酸加成盐。
• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0090972A2

  公开（公告）日：1983-10-12

  A compound of the formula (I): wherein W, and W2 each independently is a hydrogen atom or a group wherein Y is a n-C1-6 alkvlene group or a n-C1-6 alkylene group having a C1-6 alkyl group substituent; and R, and R2 each independently is a hydrogen atom or a C1-5 alkyl group, and group in group may form a saturated heterocyclic ring selected from the group consisting of morphohno. pyrrolidino, piperidino, homopiperidino and piperazino groups. and the saturated heterocyclic ring except the morpholino group may have at least one C1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z, is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C1-3 alkyl group or a methoxy group; Z2 is a hydrogen atom or an amino group; when W, and W2 are both hydrogen atoms, Z, is a hydroxyl group or an iodine atom and Z2 is hydrogen atom, or Z, and 22 are both amino groups; When Z, and 22 are both hydrogen atoms, the group in either W, or W2 is a morpholino group; when Z, is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z2 is a hydrogen atom; when Z, is an amino group, Z2 is a hydrogen atom or an amino group; when Z, is a methyl group, a methoxy group or an amino group, Z, is in the 5-position; when Z, is an iodine atom, Z, is in the 5- or 7-position; and when Z, and Z2 are both amino groups. Z, and Z2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  式 (I) 的化合物： 其中 W和W2各自独立地为氢原子或基团，其中 其中 Y 是 n-C1-6 烯基或具有 C1-6 烷基取代基的 n-C1-6 烯基；以及 R 和 R2 各自独立地是氢原子或 C1-5 烷基，且 中的基团 除吗啉基外，饱和杂环可具有至少一个 C1-4 烷基、羟基或卤原子作为取代基； Z 是氢原子、氯原子、溴原子、碘原子、羟基、氨基、C1-3 烷基或甲氧基； Z2 是氢原子或氨基； 当 W 和 W2 都是氢原子时，Z 是羟基或碘原子，Z2 是氢原子，或 Z 和 22 都是氨基； 当 Z 和 22 均为氢原子时，则 当 Z 和 22 均为氢原子时，W 或 W2 中的基团为吗啉基； 当 Z 为氯原子、羟基、碘原子、甲基或甲氧基时，Z2 为氢原子； 当 Z 为氨基时，Z2 为氢原子或氨基； 当 Z 是甲基、甲氧基或氨基时，Z 在 5 位；当 Z 是碘原子时，Z 在 5 或 7 位；当 Z 和 Z2 都是氨基时。Z和Z2分别位于5和7位；及其生理学上可接受的酸加成盐。
• POLYSACCHARIDE DERIVATIVE/MAGNETIC METAL OXIDE COMPOSITE
  申请人：MEITO SANGYO KABUSHIKI KAISHA

  公开号：EP0928809A1

  公开（公告）日：1999-07-14

  The present invention provides a polysaccharide-magnetic metal oxide complex consisting of a polysaccharide derivative obtained by carboxyalkyl-etherifying and unsubstituted or substituted aminoalkyl-etherifying a polysaccharide (the above carboxy group and/or amino group may be of a salt form) and a magnetic metal oxide. The above complex has a slow blood clearance and a low toxicity and is useful as a nuclear magnetic resonance imaging contrast medium.

  本发明提供了一种多糖-磁性金属氧化物复合物，由羧基烷基醚化和未取代或取代氨基烷基醚化多糖（上述羧基和/或氨基可以是盐形式）得到的多糖衍生物和磁性金属氧化物组成。上述复合物的血液清除速度慢，毒性低，可用作核磁共振成像造影剂。
• Optisch aktive Salze aus einem substituierten Thiazolidin-4-carboxylat und 3-Chlor-2-hydroxypropyltrimethylammonium, deren Herstellung und Verwendung
  申请人：Degussa Aktiengesellschaft

  公开号：EP0312726B1

  公开（公告）日：1992-04-08